Holen Sie sich die Stockscreener-App
239.65
3.00%
-7.40
Handel nachbörslich:
239.65
Ascendis Pharma A S Aktie (ASND) Neueste Nachrichten
Ascendis Pharma A/S (ASND) Stock Analysis: Riding the Wave of Impressive Revenue Growth and Analyst Optimism - DirectorsTalk Interviews
Ascendis Pharma’s Skytrofa gains FDA approval for growth hormone deficiency - MSN
ASNDAscendis Pharma A/S Stock Price and Quote - Finviz
Liquidity Mapping Around (ASND) Price Events - Stock Traders Daily
ASND Technical Analysis | Trend, Signals & Chart Patterns | ASCENDIS PHARMA A/S (NASDAQ:ASND) - ChartMill
ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC - MEXC
What Does YUVIWEL's FDA Approval Mean for Ascendis Pharma - Kavout
Citigroup initiates coverage of Ascendis Pharma A (ASND) with buy recommendation - MSN
Ascendis Pharma Earnings Call Highlights Growth Momentum - TipRanks
ASND Initiates Coverage by Citigroup -- Announces Price Target o - GuruFocus
Ascendis Pharma A/SOrdinary Share (NQ: ASND - The Chronicle-Journal
Assessing Ascendis Pharma (ASND) Valuation After Recent Soft Trading And Perceived Discount - simplywall.st
Ascendis Pharma initiated with a Buy at Citi - TipRanks
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $240.5 - 富途牛牛
Which Is a Better Investment, Ascendis Pharma A/S or Biogen Inc. Stock? - AAII
Ascendis Pharma A/S (ASND) Stock Analysis: Impressive Revenue Growth and Strong Buy Ratings Signal a Promising Future - DirectorsTalk Interviews
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate - ChartMill
ASND Maintained by Evercore ISI Group -- Price Target Raised to $329 - GuruFocus
Janus Henderson (NASDAQ: ASND) reports 3.72M ADS stake - Stock Titan
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $329 - 富途牛牛
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI - TipRanks
Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position - simplywall.st
We Think Shareholders Should Be Aware Of Some Factors Beyond Ascendis Pharma's (NASDAQ:ASND) Profit - 富途牛牛
Ascendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma - AOL.com
Capital International holds 2.01M shares of Ascendis Pharma (ASND) - Stock Titan
Ascendis Pharma grants 31,250 employee warrants at $237.65 per share By Investing.com - Investing.com India
Ascendis Pharma grants 31,250 employee warrants at $237.65 per share - Investing.com
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants - TipRanks
Ascendis Pharma (ASND) grants 31,250 new employee share warrants - Stock Titan
Major Insider Move Shakes Up Ascendis Pharma Investors - TipRanks
Ascendis Pharma A/S(ASND.US) Officer Sells US$4.64 Million in Common Stock - Moomoo
Ascendis Pharma (ASND) officer exits 19,460 shares in open-market sale - Stock Titan
Number of shareholders of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Number of shareholders of Ascendis Pharma A/S – GETTEX:A710 - TradingView
[144] Ascendis Pharma A/S SEC Filing - Stock Titan
ASND Maintained by Barclays -- Price Target Raised to $345 - GuruFocus
Why (ASND) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345 - 富途牛牛
Ascendis sells specific US voucher for close to USD 200m - medwatch.com
Ascendis Pharma price target raised to $345 from $342 at Barclays - TipRanks
Ascendis Pharma A/S (ASND) Stock Report: Analyst Ratings Suggest 24% Upside Potential - DirectorsTalk Interviews
Ascendis Pharma hits milestone posting EUR 25m profit - medwatch.com
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Momentum - simplywall.st
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $326 - 富途牛牛
Ascendis Pharma A/S Q1 2026 earnings preview - MSN
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript - Insider Monkey
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Ascendis Pharma (ASND) Profit Swing To €10.2 EPS Tests Earnings Quality Concerns - simplywall.st
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):